Moleculin Biotech and Walter Klemp News

This is selected news for Moleculin Biotech and Walter Klemp, which are filed under Sectors / Healthtech and People, respectively. There are 34 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/12/2022 Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript
Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Walter Klemp ‚Ai Chairman and Chief Executive Officer Jonathan Foster ‚Ai Executive Vice President and Chief Financial Officer Conference Call Participants Jonathan Aschoff ...
Seeking Alpha
11/7/2022 Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast
... call and live audio webcast to discuss the operational and financial results at 5:00 PM ET that same day. The call will be led by Walter Klemp , Chairman and Chief Executive Officer of Moleculin and Jonathan Foster , Executive VP & Chief Financial Officer of Moleculin. Interested participants and investors may access ...
PR Newswire
9/7/2022 Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON , Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , ( Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp , President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright ...
PR Newswire
9/7/2022 Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Web Chronicle Today
Moleculin Biotech, Inc., (Nasdaq: MBRX) (‚AuMoleculin‚Au or the ‚AuCompany‚Au), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global ...
webchronicletoday.com
9/6/2022 Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON , Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , ( Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the ...
PR Newswire
9/6/2022 2022-09-06 | NDAQ:MBRX | Press Release | Moleculin Biotech Inc.
... WP1122 for the treatment of Glioblastoma Multiforme ("GBM"). "The receipt of Orphan Drug Designation represents an important milestone for our promising WP1122 development program," commented Walter Klemp , Chairman and Chief Executive Officer of Moleculin. "Given the progress of our Phase 1 clinical trial in healthy volunteers, the strong preclinical data ...
stockhouse.com
4/8/2021 Sound Pharmaceuticals to launch NIH-funded Covid-19 oral therapeutic trial
... Furthermore, the company will assess whether SPI-1005 can enhance the body's inflammatory and cellular immune response to Covid-19. In a separate development, Moleculin Biotech and IQVIA Biotech are set to initiate potential clinical trials of the former's drug, WP1122, for treating Covid-19. Moleculin Biotech chairman ...
worldpharmatoday.com
4/6/2021 Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
... is intended to facilitate the advancement into possible clinical trials for WP1122 with the objective of determining our drug's potential for treating COVID-19," commented Walter Klemp , Moleculin's Chairman and CEO. "We continue to believe the best possible pathway for development may be outside the US, given the FDA's requirement ...
tncontentexchange.com
10/13/2020 Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
HOUSTON , Oct. 13, Moleculin Biotech, Inc., (Nasdaq: MBRX ) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 ...
PR Newswire
10/13/2020 Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial | Texas | kdhnews.com
... 8 mg/kg with no adverse events related to WP1066 and the study will now proceed to the next higher dose of 16 mg/kg. Walter Klemp , Chairman and CEO of Moleculin, stated, "On the heels of our recent positive announcement regarding the progress of the pediatric brain tumor trial ...
tncontentexchange.com
10/5/2020 Moleculin Appoints Elizabeth Cermak to Board of Directors | Texas | kdhnews.com
Moleculin Appoints Elizabeth Cermak to Board of Directors By Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. By Moleculin Biotech, Inc. Save HOUSTON , Oct. 5 . 2020 /PRNewswire ...
tncontentexchange.com
9/14/2020 Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
... studies for the treatment of COVID-19 in such high demand, we are excited to begin an in vivo study involving our WP1122 portfolio," commented Walter Klemp , Chairman and CEO of Moleculin. "Even though we may have initial observations earlier, having the final data readout in December will push the ...
PR Newswire
9/14/2020 Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122 By Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. By Moleculin Biotech, Inc. Save HOUSTON , Sept. 14 ...
tncontentexchange.com
9/14/2020 Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
... studies for the treatment of COVID-19 in such high demand, we are excited to begin an in vivo study involving our WP1122 portfolio," commented Walter Klemp , Chairman and CEO of Moleculin. "Even though we may have initial observations earlier, having the final data readout in December will push the ...
gurufocus.com
8/27/2020 Moleculin to Present at LD Micro 500 Virtual Investor Conference
HOUSTON , Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual Investor Conference ...
PR Newswire
8/27/2020 Moleculin to Present at LD Micro 500 Virtual Investor Conference
PR Newswire HOUSTON, Aug. 27, 2020 HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual ...
gurufocus.com
8/12/2020 Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX ) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update. Management Discussion Walter Klemp , Chairman and ...
PR Newswire
7/21/2020 Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
... humans rather than the artificially high levels of glucose often used to accelerate in vitro testing. "This additional testing was important for several reasons," commented Walter Klemp , Chairman and CEO of Moleculin. "Having validation in yet another virus host cell line provides additional confidence in the antiviral activity we are ...
PR Newswire
7/15/2020 Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has entered into an agreement with Sterling Pharma USA LLC for US production of WP1122 to support its ...
PR Newswire
7/2/2020 Moleculin Provides Update on Annamycin Clinical Development
... level of 300 to 360 mg/m 2 , or possibly higher, before we begin to see a solid therapeutic window for Annamycin in AML," commented Walter Klemp , Chairman and CEO of Moleculin. "Now, with 5 clinical sites open in Poland , the European trial is in the best position to complete ...
PR Newswire
6/25/2020 Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
HOUSTON , June 25, Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American Association of Cancer Research (AACR) Annual Meeting held from June 22 nd -24 ...
PR Newswire
6/25/2020 Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
... initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death," commented Walter Klemp , Chairman and CEO of Moleculin. "This research also sheds light on why doxorubicin, the current standard of care for many types of cancer ...
tncontentexchange.com
6/25/2020 Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
Data Presented at the AACR Annual Meeting PR Newswire HOUSTON, June 25, 2020 HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American Association of ...
6/23/2020 Moleculin to Present at the Life Sciences Investor Forum
HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will present at the Life Sciences Investor Forum being held virtually on June 25 ...
PR Newswire
6/23/2020 Moleculin to Present at the Life Sciences Investor Forum
Moleculin to Present at the Life Sciences Investor Forum By Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. By Moleculin Biotech, Inc. Save HOUSTON , June 23, 2020 ...
tncontentexchange.com